eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2022-09-29 15 3 1745 1749 10.13005/bpj/2513 45567 article Pompini Agustina Sitompul 1 Nina Mariana 1 Ervan Budiman 1 Dian Wahyu Tanjung 1 Betha Ariesanty 1 Teguh Sarry Hartono 1 Sulianti Saroso Infectious Disease, Jakarta, Indonesia Hospital workers were at high risk for SARS-CoV-2 infection and the first population with authorized access to the three doses of vaccination against SARS-CoV-2 antigen. The study was aimed to compare SARS-CoV-2 antibody levels among hospital workers receiving the three doses of Covid-19 vaccines with a history of Covid-19 infection versus those without a history of infection. A cross sectional study was conducted at the Sulianti Saroso Infectious Disease Hospital (SSIDH) in December 2021. The inclusion criteria were hospital workers in both subjects with and without previous Covid-19 infection and those who had received 3 doses of Covid-19 vaccines. Anti SARS-CoV-2 antibody levels measured by the Architect of SARS-CoV-2 IgG II Quant.  There were 75 participants in the study, the median of anti SARS CoV-2 levels reported 8724.4 AU/mL (3396.8, 15773.2 AU/mL, Interquartile range). They were divided into 2 groups according to the status of prior Covid-19 infection, hospital workers with and without previous of Covid-19 infection. There was no significance difference in antibody less than 25.000 AU/mL between hospital worker with and without previous Covid-19 infection (p=1,000). Meanwhile, the median of antibody levels was seen in the interval between the 3^rd dose of vaccine within 1 month; 2 to 3 months; 4 to 5 months before the antibody measurement (14576.5 AU/mL;12407.4 AU/mL; 5778.1 AU/mL, respectively). In this study, after three doses of Covid-19 vaccines, there was no significance difference in antibody levels of hospital worker with and without previous Covid-19 infection. https://biomedpharmajournal.org/vol15no3/quantitative-antibody-levels-in-hospital-workers-after-receiving-three-doses-of-covid-19-vaccines/ Abbott Architect Antigen  SARS-CoV-2 Vaccination